CCO faculty Dr. Jonathan Kay’s viewpoint on data from 2019 ACR/ARP on novel approaches for treatment of RA
CCO faculty Dr. Stanley Cohen’s viewpoint on data from 2019 ACR/ARP on investigational and approved JAK inhibitors for RA
7-year baricitinib safety data in RA patients consistent with earlier reports and acceptable considering efficacy from 2019 ACR, as reported by CCO; safety evaluations ongoing
Latest data on IRAK4 inhibitor PF-06650833 in moderately to severely active RA presented at ACR/ARHP 2019 as reported by Clinical Care Options (CCO)
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.